Browse > Article

Suppression of DNCB-induced Dermatitis in NC/Nga Murine Model by Biheoonsupbang  

Kim, Jung-Hwan (Department of Pathology, College of Oriental Medicine, Daejeon University)
Choi, Jeong-June (Department of Pathology, College of Oriental Medicine, Daejeon University)
Koo, Young-Sun (Department of Internal Medicine, College of Oriental Medicine, Daejeon University)
Roh, Seong-Soo (Laboratory of Herbology, College of Oriental Medicine, Daejeon University)
Kim, Dong-Hee (Department of Pathology, College of Oriental Medicine, Daejeon University)
Publication Information
Journal of Physiology & Pathology in Korean Medicine / v.21, no.3, 2007 , pp. 714-720 More about this Journal
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by inflammatory cell infiltration in the skin. This study was performed to assess the therapeutic effects of BHOSB on the DNCB-induced dermatitis in NC/Nga mice, characterized by the onset of AD along with an increase the number of inflammatory cells and dysregulation of inflammatory mediators including cytokines and chemokines. BHOSB administration significantly reduced clinical dermatitis severity including pruritus, edema, eczematous and erythema. Histological findings indicated that the thickening of epidermis/dermis and dermal infiltration of inflammatory cells including mast cells were dramatically reduced. The suppression of dermatitis by BHOSB was accompanied by a decrease in the number of CD11b$^+$/Gr-1$^+$ immune cells in skin but not CD3$^+$/CCR3$^+$ cells. However, the number of CD3$^+$ cells was increased in BHOSB administrated NC/Nga mice. Oral administration of BHOSB significantly reduced the level of IL-6, TNF-a and eotaxin 2 mRNA in skin. These data suggest that BHOSB may be effective therapeutic agents for the treatment of AD.
Keywords
Biheoonsupbang; atopic dermatitis; NC/Nga mice; immune modulation; granulocyte; cytokines;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Sampson, H.A. Atopic dermatitis. Ann Allergy 69(6): 469-479, 1992
2 Pastore, S., Mascia, F., Giustizieri, M.L., Giannetti, A. and Girolomoni, G. Pathogenetic mechanisms of atopic dermatitis. Arch Immunol Ther Exp (Warsz) 48(6):497-504, 2000
3 Kitaura, J., Kinoshita, T., Matsumoto, M., Chung, S., Kawakami, Y., Leitges, M., Wu, D., Lowell, C.A. and Kawakami, T. IgE- and IgE+ Ag-mediated mast cell migration in an autocrine/paracrine fashion. Blood 105(8):3222-3229, 2005   DOI   ScienceOn
4 王保方 外. 皮膚病中醫診斷學, 人民衛生出版社, p 23, 24, 2000
5 Robert, C. and Kupper, T.S. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 341(24):1817-1828, 1999   DOI   ScienceOn
6 Clevers, H., Alarcon, B., Wileman, T. and Terhorst, C. The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol 6: 629-662, 1988   DOI   ScienceOn
7 Bandeira-Melo, C., Bozza, P.T. and Weller, P.F. The cellular biology of eosinophil eicosanoid formation and function. J Allergy Clin Immunol 109(3):393-400, 2002   DOI   ScienceOn
8 Vestergaard, C., Yoneyama, H. and Matsushima, K. The NC/Nga mouse: a model for atopic dermatitis. Mol Med Today 6(5):209-210, 2000   DOI   ScienceOn
9 朴俊華. 皮膚性病科節技, 科學技術文獻出版社, p 2, 33, 42, 80, 2002
10 Schmid-Grendelmeier, P., Altznauer, F., Fischer, B., Bizer, C., Straumann, A., Menz, G., Blaser, K., Wuthrich, B. and Simon, H.U. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol 169(2):1021-1027, 2002   DOI
11 Daniels, J. and Harper, J. The epidemiology of atopic dermatitis. Hosp Med 63(11):649-652, 2002   DOI
12 Silny, W. Atopic dermatitis. IV. Granulocyte chemotaxis. Przegl Dermatol 70(5-6):475-480, 1983
13 대한동의생리학회. 동의생리학, 일중사, p 332, 337, 2005
14 Williams, H.C. Clinical practice. Atopic dermatitis. N Engl J Med 352(22):2314-2324, 2005   DOI
15 Holden, C.A. and WE, P. Atopic dermatitis Blcackwell Science, Oxford, 1998
16 Mihm, M.C. Jr., Soter, N.A., Dvorak, H.F. and Austen, K.F. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 67(3):305-312, 1976   DOI   ScienceOn
17 Cooper, K.D. Atopic dermatitis: recent trends in pathogenesis and therapy. J Invest Dermatol 102(1):128-137, 1994   DOI   ScienceOn
18 Heishi, M., Imai, Y., Katayama, H., Hashida, R., Ito, M., Shinagawa, A. and Sugita, Y. Gene expression analysis of atopic dermatitis-like skin lesions induced in NC/Nga mice by mite antigen stimulation under specific pathogen-free conditions. Int Arch Allergy Immunol 132(4):355-363, 2003   DOI   ScienceOn
19 Hu, Z.Q., Kobayashi, K., Zenda, N. and Shimamura, T. Tumor necrosis factor-alpha- and interleukin-6-triggered mast cell development from mouse spleen cells. Blood 89(2):526-533, 1997
20 한방병리학교재편찬위원회. 한방병리학, 한의문화사, pp 52-57, 2007
21 Leung, D.Y. and Bieber, T. Atopic dermatitis. Lancet 361(9352):151-160, 2003   DOI   ScienceOn
22 Plotz, S.G., Simon, H.U., Darsow, U., Simon, D., Vassina, E., Yousefi, S., Hein, R., Smith, T., Behrendt, H. and Ring, J. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349(24):2334-2339, 2003   DOI
23 張志禮. 張志禮皮膚病臨床經驗輯要, 中國醫藥科技出版社, p 15, 23, 43, 2002
24 Leung, D.Y. and Soter, N.A. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 44(1 Suppl):S1-S12, 2001   DOI   ScienceOn
25 Yawalkar, N., Uguccioni, M., Scharer, J., Braunwalder, J., Karlen, S., Dewald, B., Braathen, L.R. and Baggiolini, M. Enhanced expression of eotaxin and CCR3 in atopic dermatitis. J Invest Dermatol 113(1):43-48, 1999   DOI   ScienceOn
26 Meagher, L.J., Wines, N.Y. and Cooper, A.J. Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy. Australas J Dermatol 43(4):247-254, 2002   DOI   ScienceOn